Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Bone Density"" wg kryterium: Temat


Starter badań:

Tytuł :
Effect of TNF inhibitors with bisphosphonates vs bisphosphonates alone on bone mineral density and bone and cartilage biomarkers at 1 year in patients with rheumatoid arthritis: A prospective study.
Autorzy :
Nagase Y; Department of Rheumatic Surgery, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan.
Nagashima M; Department of Rheumatology, Katsushika Rehabilitation Hospital, Katsushika-ku, Tokyo, Japan.
Shimane K; Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan.
Nishikawa T; Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan.
Naito M; Department of Orthopaedic Surgery, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan.
Tanaka S; Department of Orthopaedic Surgery, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Pokaż więcej
Źródło :
Modern rheumatology [Mod Rheumatol] 2022 Apr 18; Vol. 32 (3), pp. 517-521.
Typ publikacji :
Journal Article
MeSH Terms :
Arthritis, Rheumatoid*/diagnostic imaging
Arthritis, Rheumatoid*/drug therapy
Arthritis, Rheumatoid*/metabolism
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Bone Resorption*
Biomarkers ; Bone Density ; Cartilage/metabolism ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Femur Neck ; Humans ; Prospective Studies ; Tumor Necrosis Factor Inhibitors
Czasopismo naukowe
Tytuł :
Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Autorzy :
Shane E; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Shiau S; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
Recker RR; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Lappe JM; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Agarwal S; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Kamanda-Kosseh M; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Bucovsky M; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Stubby J; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Cohen A; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Pokaż więcej
Źródło :
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2022 Mar 24; Vol. 107 (4), pp. e1528-e1540.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Bone Density Conservation Agents*
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/drug therapy
Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Female ; Humans ; Lumbar Vertebrae/diagnostic imaging ; Teriparatide
Czasopismo naukowe
Tytuł :
The effect of osteoporosis treatment on bone mass.
Autorzy :
Appelman-Dijkstra NM; Department of Internal Medicine; Division Endocrinology and Center for Bone Quality, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: .
Oei HLDW; Department of Internal Medicine; Division Endocrinology and Center for Bone Quality, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Department of Internal Medicine, Jan van Goyen Medical Center, Amsterdam, the Netherlands. Electronic address: .
Vlug AG; Department of Internal Medicine; Division Endocrinology and Center for Bone Quality, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Jan van Goyen Medical Center, Amsterdam, the Netherlands. Electronic address: .
Winter EM; Department of Internal Medicine; Division Endocrinology and Center for Bone Quality, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Best practice & research. Clinical endocrinology & metabolism [Best Pract Res Clin Endocrinol Metab] 2022 Mar; Vol. 36 (2), pp. 101623. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Bone Resorption*
Fractures, Bone*/epidemiology
Osteoporosis*/drug therapy
Bone Density ; Denosumab/therapeutic use ; Humans
Czasopismo naukowe
Tytuł :
Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.
Autorzy :
Hori M; Department of Nephrology, Masuko Memorial Hospital, 35-28 Takehashi-cho, Nakamura-ku, Nagoya, Aichi, 453-8566, Japan. .
Yasuda K; Department of Nephrology, Masuko Memorial Hospital, 35-28 Takehashi-cho, Nakamura-ku, Nagoya, Aichi, 453-8566, Japan.
Takahashi H; Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Kondo C; Department of Nephrology, Masuko Memorial Hospital, 35-28 Takehashi-cho, Nakamura-ku, Nagoya, Aichi, 453-8566, Japan.
Shirasawa Y; Department of Nephrology, Masuko Memorial Hospital, 35-28 Takehashi-cho, Nakamura-ku, Nagoya, Aichi, 453-8566, Japan.
Ishimaru Y; Department of Nephrology, Masuko Memorial Hospital, 35-28 Takehashi-cho, Nakamura-ku, Nagoya, Aichi, 453-8566, Japan.
Sekiya Y; Department of Nephrology, Masuko Memorial Hospital, 35-28 Takehashi-cho, Nakamura-ku, Nagoya, Aichi, 453-8566, Japan.
Morozumi K; Department of Nephrology, Masuko Memorial Hospital, 35-28 Takehashi-cho, Nakamura-ku, Nagoya, Aichi, 453-8566, Japan.
Maruyama S; Department of Nephrology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2022 May 11; Vol. 12 (1), pp. 7781. Date of Electronic Publication: 2022 May 11.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Hypocalcemia*/chemically induced
Alkaline Phosphatase ; Biomarkers ; Bone Density ; Bone Remodeling ; Denosumab/adverse effects ; Humans ; Renal Dialysis/adverse effects ; Tartrate-Resistant Acid Phosphatase
Czasopismo naukowe
Tytuł :
Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
Autorzy :
Cui L; Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.
Xia W; Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.
Yu C; Chugai Pharma China CO., LTD, Shanghai, 200021, China.
Dong S; Chugai Pharma China CO., LTD, Shanghai, 200021, China.
Pei Y; Department of Endocrinology, First Medical Center, General Hospital of the People's Liberation Army of China, Beijing, 100039, China. .
Pokaż więcej
Źródło :
Archives of osteoporosis [Arch Osteoporos] 2022 May 05; Vol. 17 (1), pp. 74. Date of Electronic Publication: 2022 May 05.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/drug therapy
Vitamin D*/adverse effects
Vitamin D*/analogs & derivatives
Bone Density ; Humans ; Hypercalciuria/epidemiology ; Spinal Fractures/epidemiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years.
Autorzy :
Farlay D; INSERM, UMR 1033, University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Rizzo S; INSERM, UMR 1033, University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Dempster DW; Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.; Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA.
Huang S; Clinical Development, Amgen Inc., Thousand Oaks, CA, USA.
Chines A; Clinical Development, Amgen Inc., Thousand Oaks, CA, USA.
Brown JP; CHU de Quebec Research Centre, Laval University, Quebec City, Canada.
Boivin G; INSERM, UMR 1033, University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Pokaż więcej
Źródło :
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2022 May; Vol. 37 (5), pp. 856-864. Date of Electronic Publication: 2022 Mar 24.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Osteoporosis, Postmenopausal*/pathology
Bone Density ; Cross-Sectional Studies ; Denosumab/therapeutic use ; Female ; Humans ; Ilium/pathology ; Minerals ; Postmenopause
Czasopismo naukowe
Tytuł :
A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment.
Autorzy :
Jensen P; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Jakobsen LH; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Bøgsted M; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Baech J; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Lykkeboe S; Department of Clinical Biochemistry, and.
Severinsen MT; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Vestergaard P; Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark.; Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark; and.; Steno Diabetes Center North Denmark, Aalborg, Denmark.
El-Galaly TC; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2022 Apr 26; Vol. 6 (8), pp. 2549-2556.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Lymphoma*/complications
Lymphoma*/drug therapy
Osteoporosis*/chemically induced
Osteoporosis*/prevention & control
Alendronate/adverse effects ; Bone Density ; Female ; Glucocorticoids/therapeutic use ; Humans ; Male
Czasopismo naukowe
Tytuł :
Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study.
Autorzy :
Tanaka I; Nagoya Rheumatology Clinic, Initiative for Rheumatology and Osteoporosis, Nagoya, Aichi, Japan.
Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
Soen S; Soen Orthopedics, Osteoporosis, and Rheumatology Clinic, Kobe, Hyogo, Japan.
Oshima H; Graduate School of Nursing, Tokyo Healthcare University, Tokyo, Japan.; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Pokaż więcej
Źródło :
Modern rheumatology [Mod Rheumatol] 2022 Apr 18; Vol. 32 (3), pp. 634-640.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Osteoporosis*/prevention & control
Alendronate/therapeutic use ; Bone Density ; Glucocorticoids/adverse effects ; Humans ; Primary Prevention ; Teriparatide/therapeutic use
Czasopismo naukowe
Tytuł :
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Autorzy :
Shen J; Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China (mainland).
Ke Z; Chugai Pharma China Co., Ltd., Shanghai, China (mainland).
Dong S; Chugai Pharma China Co., Ltd., Shanghai, China (mainland).
Lv M; Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China (mainland).
Yuan Y; Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China (mainland).
Song L; Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China (mainland).
Wu K; Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China (mainland).
Xu K; Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China (mainland).
Hu Y; Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China (mainland).; Center of Clinical Epidemiology and Evidence-Based Medicine, Fudan University, Shanghai, China (mainland).
Pokaż więcej
Źródło :
Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2022 Apr 17; Vol. 28, pp. e935491. Date of Electronic Publication: 2022 Apr 17.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Hip Fractures*/drug therapy
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/drug therapy
Spinal Fractures*/drug therapy
Bone Density ; Female ; Humans ; Ibandronic Acid/pharmacology ; Ibandronic Acid/therapeutic use ; Network Meta-Analysis ; Risedronic Acid/pharmacology ; Risedronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Management of patients at very high risk of osteoporotic fractures through sequential treatments.
Autorzy :
Curtis EM; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
Reginster JY; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium.; Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart Tilman B23, 4000, Liège, Belgium.
Al-Daghri N; Biochemistry Department, College of Science, King Saud University, 11451, Riyadh, Kingdom of Saudi Arabia.
Biver E; Division of Bone Diseases, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Brandi ML; F.I.R.M.O, Italian Foundation for the Research on Bone Diseases, Florence, Italy.
Cavalier E; Department of Clinical Chemistry, University of Liege, CHU de Liège, Liège, Belgium.
Hadji P; Center of Bone Health, Frankfurt, Germany.; Philipps-University of Marburg, Marburg, Germany.
Halbout P; International Osteoporosis Foundation, Nyon, Switzerland.
Harvey NC; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Hiligsmann M; Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Javaid MK; NDORMS, University of Oxford, Windmill Road, Oxford, UK.
Kanis JA; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK.
Kaufman JM; Department of Endocrinology, Ghent University Hospital, Gent, Belgium.
Lamy O; University of Lausanne, UNIL, CHUV, Lausanne, Switzerland.
Matijevic R; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.; Clinical Center of Vojvodina, Clinic for Orthopedic Surgery, Novi Sad, Serbia.
Perez AD; Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of Barcelona and CIBERFES, Instituto Carlos III, Madrid, Spain.
Radermecker RP; Department of Diabetes, Nutrition and Metabolic Disorders, Clinical Pharmacology, University of Liege, CHU de Liège, Liège, Belgium.
Rosa MM; Faculty of Medicine, University of Lisboa, Lisbon, Portugal.
Thomas T; Department of Rheumatology, Hôpital Nord, CHU Saint-Etienne, Saint-Etienne, France.; INSERM U1059, Université de Lyon, Université Jean Monnet, Saint-Etienne, France.
Thomasius F; Center of Bone Health, Frankfurt, Germany.
Vlaskovska M; Medical Faculty, Department of Pharmacology and Toxicology, Medical University Sofia, Sofia, Bulgaria.
Rizzoli R; Division of Bone Diseases, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Cooper C; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK. .; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. .; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. .
Pokaż więcej
Źródło :
Aging clinical and experimental research [Aging Clin Exp Res] 2022 Apr; Vol. 34 (4), pp. 695-714. Date of Electronic Publication: 2022 Mar 24.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anabolic Agents*/pharmacology
Anabolic Agents*/therapeutic use
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/complications
Osteoporosis*/drug therapy
Osteoporotic Fractures*/drug therapy
Osteoporotic Fractures*/prevention & control
Bone Density ; Humans
Czasopismo naukowe
Tytuł :
Osteoporosis in men.
Autorzy :
Vilaca T; Department of Oncology and Metabolism, Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK. Electronic address: .
Eastell R; Department of Oncology and Metabolism, Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK.
Schini M; Department of Oncology and Metabolism, Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK.
Pokaż więcej
Źródło :
The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2022 Apr; Vol. 10 (4), pp. 273-283. Date of Electronic Publication: 2022 Mar 02.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/diagnosis
Osteoporosis*/epidemiology
Osteoporosis*/therapy
Bone Density ; Diphosphonates/therapeutic use ; Female ; Humans ; Male ; Teriparatide/therapeutic use
Czasopismo naukowe
Tytuł :
Bone Health in Osteosarcoma at Presentation and Its Impact on Cancer Treatment: A Case Series of 3 Pediatric Patients.
Autorzy :
Malcolmson C; Division of Pediatric Hematology-Oncology, Department of Pediatrics.
Lautatzis ME; Division of Pediatric Endocrinology, Department of Pediatrics.
Malkiel S; Department of Pediatric Hematology-Oncology, The Chaim Sheba Medical Center, Tel-Aviv University Sackler School of Medicine, Tel-Hashomer, Israel.
Lenherr-Taube N; Division of Pediatric Endocrinology, Department of Pediatrics.
Traubici J; Department of Diagnostic Imaging, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada.
Gupta A; Division of Pediatric Hematology-Oncology, Department of Pediatrics.
Hopyan S; Division of Orthopedics, Department of Surgery.
Sochett E; Division of Pediatric Endocrinology, Department of Pediatrics.
Grant R; Division of Pediatric Hematology-Oncology, Department of Pediatrics.
Pokaż więcej
Źródło :
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2022 Apr 01; Vol. 44 (3), pp. e782-e787.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Bone Density Conservation Agents*
Bone Neoplasms*/complications
Bone Neoplasms*/therapy
Osteoporosis*
Osteosarcoma*/complications
Osteosarcoma*/drug therapy
Bone Density ; Child ; Diphosphonates ; Humans
Czasopismo naukowe
Tytuł :
Effect of Teriparatide on Bone Mineral Density and Trabecular Bone Score in Type 2 Diabetic Patients with Osteoporosis: A Retrospective Cohort Study.
Autorzy :
Munekawa C; Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Hashimoto Y; Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Kitagawa N; Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.; Department of Diabetology, Kameoka Municipal Hospital, Kameoka 621-8585, Japan.
Osaka T; Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.; Department of Endocrinology and Diabetology, Ayabe City Hospital, Ayabe 623-0011, Japan.
Hamaguchi M; Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Fukui M; Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Pokaż więcej
Źródło :
Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2022 Mar 26; Vol. 58 (4). Date of Electronic Publication: 2022 Mar 26.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/therapeutic use
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Osteoporosis*/drug therapy
Bone Density ; Cancellous Bone ; Diphosphonates/therapeutic use ; Humans ; Lumbar Vertebrae ; Retrospective Studies ; Teriparatide/pharmacology ; Teriparatide/therapeutic use
Czasopismo naukowe
Tytuł :
Treatment Challenges When Stopping Denosumab.
Autorzy :
McDonough A; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Malomo K; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Brennan F; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Fallon N; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Steen G; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Maher N; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
O'Carroll C; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Walsh JB; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Lannon R; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
McCarroll K; Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.
Pokaż więcej
Źródło :
Irish medical journal [Ir Med J] 2022 Mar 16; Vol. 115 (3), pp. 567. Date of Electronic Publication: 2022 Mar 16.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Osteoporosis, Postmenopausal*/chemically induced
Osteoporosis, Postmenopausal*/drug therapy
Aged ; Bone Density ; Denosumab/adverse effects ; Diphosphonates/adverse effects ; Female ; Humans ; Middle Aged ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Drug therapy for osteoporosis in older adults.
Autorzy :
Reid IR; Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Auckland District Health Board, Auckland, New Zealand. Electronic address: .
Billington EO; Division of Endocrinology and Metabolism, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2022 Mar 12; Vol. 399 (10329), pp. 1080-1092.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/drug therapy
Aged ; Bone Density ; Denosumab/therapeutic use ; Diphosphonates/therapeutic use ; Female ; Humans ; Teriparatide/therapeutic use
Czasopismo naukowe
Tytuł :
Drug Treatment of Low Bone Mass and Other Bone Conditions in Pediatric Patients.
Autorzy :
Costi S; University of Milan, Milan, Italy.
Giani T; University of Milan, Milan, Italy.; Department of Clinical Sciences and Community Health; and Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy.
Orsini F; University of Milan, Milan, Italy.
Cimaz R; ASST Gaetano Pini-CTO, Milan, Italy. .; Department of Clinical Sciences and Community Health; and Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy. .
Pokaż więcej
Źródło :
Paediatric drugs [Paediatr Drugs] 2022 Mar; Vol. 24 (2), pp. 103-119. Date of Electronic Publication: 2022 Jan 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/drug therapy
Osteoporosis*/etiology
Bone Density ; Child ; Denosumab/therapeutic use ; Diphosphonates/therapeutic use ; Humans ; Risk Factors
Czasopismo naukowe
Tytuł :
Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS).
Autorzy :
Seefried L; Orthopedic Center for Musculoskeletal Research, Orthopedic Department, University of Wuerzburg, Wuerzburg, Germany.
Genest F; Orthopedic Center for Musculoskeletal Research, Orthopedic Department, University of Wuerzburg, Wuerzburg, Germany.
Baumann J; Orthopedic Center for Musculoskeletal Research, Orthopedic Department, University of Wuerzburg, Wuerzburg, Germany.
Heidemeier A; Department of Diagnostic and Interventional Radiology, University Hospital Wuerzburg, Wuerzburg, Germany.
Meffert R; Department of Trauma, Plastic, Reconstructive, and Hand Surgery, University Hospital Wuerzburg, Wuerzburg, Germany.
Jakob F; Orthopedic Center for Musculoskeletal Research, Orthopedic Department, University of Wuerzburg, Wuerzburg, Germany.
Pokaż więcej
Źródło :
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2022 Mar; Vol. 37 (3), pp. 420-427. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Cartilage Diseases*/pathology
Bone Density ; Bone Marrow/pathology ; Diphosphonates/adverse effects ; Double-Blind Method ; Humans ; Pain/drug therapy ; Vitamin D/therapeutic use ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Summary for Patients: Fracture Risk During Osteoporosis Drug Holidays.
Źródło :
Annals of internal medicine [Ann Intern Med] 2022 Mar; Vol. 175 (3), pp. I23. Date of Electronic Publication: 2022 Jan 11.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Fractures, Bone*/chemically induced
Fractures, Bone*/prevention & control
Osteoporosis*/complications
Osteoporosis*/drug therapy
Osteoporotic Fractures*/prevention & control
Bone Density ; Diphosphonates ; Humans
Czasopismo naukowe
Tytuł :
Effects of teriparatide and low-intensity aerobic exercise on osteopenia in type 2 diabetes mellitus rats.
Autorzy :
Abe K; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Miyakoshi N; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. .
Kasukawa Y; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Nozaka K; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Tsuchie H; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Sato C; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Saito H; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Shoji R; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Shimada Y; Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.
Pokaż więcej
Źródło :
Journal of bone and mineral metabolism [J Bone Miner Metab] 2022 Mar; Vol. 40 (2), pp. 229-239. Date of Electronic Publication: 2022 Jan 28.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/pharmacology
Bone Diseases, Metabolic*/therapy
Diabetes Mellitus, Type 2*/therapy
Physical Conditioning, Animal*
Teriparatide*/pharmacology
Animals ; Bone Density ; Rats
Czasopismo naukowe
Tytuł :
In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.
Autorzy :
Goetz TG; Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Nair N; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Shiau S; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
Recker RR; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Lappe JM; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Dempster DW; Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Zhou H; Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA.
Zhao B; Department of Radiology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Guo X; Department of Radiology, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
Shen W; Department of Pediatrics, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.; Institute of Human Nutrition, Columbia University Irving Medical Center, New York, NY, USA.; Columbia Magnetic Resonance Research Center (CMRRC), Columbia University, New York, NY, USA.
Nickolas TL; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Kamanda-Kosseh M; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Bucovsky M; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Stubby J; Department of Medicine, Creighton University Medical Center, Omaha, NE, USA.
Shane E; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA.
Cohen A; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, NY, New York, USA. .
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Mar; Vol. 33 (3), pp. 659-672. Date of Electronic Publication: 2021 Oct 19.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis*/etiology
Adipose Tissue ; Bone Density ; Female ; Humans ; Insulin-Like Growth Factor I ; Osteogenesis ; Teriparatide/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies